These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 24859689

  • 1. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 2. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Apr 15; 20(8):2029-34. PubMed ID: 24573551
    [Abstract] [Full Text] [Related]

  • 3. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep 15; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

  • 4. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec 15; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ.
    Arch Pathol Lab Med; 2012 Oct 15; 136(10):1201-4. PubMed ID: 23020724
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
    Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J.
    Lung Cancer; 2015 Feb 15; 87(2):89-95. PubMed ID: 25576294
    [Abstract] [Full Text] [Related]

  • 12. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA, Bubendorf L, Stahel R, Peters S.
    Expert Rev Anticancer Ther; 2013 May 15; 13(5):625-36. PubMed ID: 23617353
    [Abstract] [Full Text] [Related]

  • 13. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
    Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR.
    Lancet Oncol; 2011 Oct 15; 12(11):1004-12. PubMed ID: 21933749
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
    Yi ES, Chung JH, Kulig K, Kerr KM.
    Mol Diagn Ther; 2012 Jun 01; 16(3):143-50. PubMed ID: 22506598
    [Abstract] [Full Text] [Related]

  • 17. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.
    Clin Chem; 2016 Jan 01; 62(1):252-61. PubMed ID: 26585927
    [Abstract] [Full Text] [Related]

  • 18. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
    Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, Justice R, Keegan P, Pazdur R.
    Oncologist; 2014 Oct 01; 19(10):e5-11. PubMed ID: 25170012
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI, Gautschi O.
    Clin Lung Cancer; 2013 Sep 01; 14(5):473-80. PubMed ID: 23790969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.